- Home
- QSI vs ORIC Comparison
QSI vs ORIC Comparison
Compare QSI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- ORIC
- Stock Information
- Founded
- QSI 2013
- ORIC 2014
- Country
- QSI United States
- ORIC United States
- Employees
- QSI N/A
- ORIC N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- ORIC Health Care
- Exchange
- QSI Nasdaq
- ORIC Nasdaq
- Market Cap
- QSI 633.2M
- ORIC 633.7M
- IPO Year
- QSI N/A
- ORIC 2020
- Fundamental
- Price
- QSI $2.30
- ORIC $10.33
- Analyst Decision
- QSI Buy
- ORIC Strong Buy
- Analyst Count
- QSI 2
- ORIC 9
- Target Price
- QSI $3.25
- ORIC $18.75
- AVG Volume (30 Days)
- QSI 59.6M
- ORIC 584.3K
- Earning Date
- QSI 02-27-2025
- ORIC 03-10-2025
- Dividend Yield
- QSI N/A
- ORIC N/A
- EPS Growth
- QSI N/A
- ORIC N/A
- EPS
- QSI N/A
- ORIC N/A
- Revenue
- QSI $2,266,000.00
- ORIC N/A
- Revenue This Year
- QSI $193.90
- ORIC N/A
- Revenue Next Year
- QSI $173.18
- ORIC N/A
- P/E Ratio
- QSI N/A
- ORIC N/A
- Revenue Growth
- QSI 232.26
- ORIC N/A
- 52 Week Low
- QSI $0.61
- ORIC $6.33
- 52 Week High
- QSI $5.77
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- QSI 49.43
- ORIC 59.58
- Support Level
- QSI $2.26
- ORIC $9.69
- Resistance Level
- QSI $2.58
- ORIC $11.15
- Average True Range (ATR)
- QSI 0.53
- ORIC 0.82
- MACD
- QSI -0.12
- ORIC 0.18
- Stochastic Oscillator
- QSI 11.48
- ORIC 75.08
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.